非霍奇金淋巴瘤/弥漫性大B细胞淋巴瘤、慢性淋巴细胞白血病和多发性骨髓瘤患者的维生素D水平
Vitamin D levels in patients with non-Hodgkin lymphoma/diffuse large B-cell lymphoma, chronic lymphocytic leukemia and multiple myeloma.
作者信息
Graklanov Vasko, Popov Veselin
机构信息
First Department of Internal Diseases, Medical University of Plovdiv, Clinical Hematology Clinic, St. George University Hospital for Active Treatment, Plovdiv, Bulgaria.
Department of Clinical Oncology, Medical University of Plovdiv, Radiation Treatment Clinic, St. George University Hospital for Active Treatment, Plovdiv, Bulgaria.
出版信息
J Int Med Res. 2020 Jul;48(7):300060520943421. doi: 10.1177/0300060520943421.
PURPOSE
To investigate serum vitamin D levels in patients newly diagnosed with non-Hodgkin lymphoma/diffuse large B-cell lymphoma (NHL-DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
PATIENTS AND METHODS
We measured serum levels of vitamin D by ELISA in 103 patients prior to initiation of treatment, of whom 37 were diagnosed with MM, 32 with CLL and 34 with NHL-DLBCL.
RESULTS
Suboptimal serum vitamin D levels (<30 ng/mL) were observed in all 103 patients. In 14 patients, serum vitamin D levels were between 20 and 30 ng/mL, while all other patients had vitamin D deficiency (<20 ng/mL). Severe vitamin D deficiency (<10 ng/mL) was observed in 32.3% of NHL-DLBCL patients, 28.1% of CLL patients and 81% of MM patients.
CONCLUSION
We observed low serum vitamin D levels in the majority of patients newly diagnosed with NHL-DLBCL, CLL and MM.
目的
研究新诊断的非霍奇金淋巴瘤/弥漫性大B细胞淋巴瘤（NHL-DLBCL）、多发性骨髓瘤（MM）和慢性淋巴细胞白血病（CLL）患者的血清维生素D水平。
患者与方法
我们采用酶联免疫吸附测定法（ELISA）对103例患者治疗开始前的血清维生素D水平进行了检测，其中37例诊断为MM，32例为CLL，34例为NHL-DLBCL。
结果
103例患者均存在血清维生素D水平未达最佳状态（<30 ng/mL）的情况。14例患者的血清维生素D水平在20至30 ng/mL之间，而其他所有患者均存在维生素D缺乏（<20 ng/mL）的情况。32.3%的NHL-DLBCL患者、28.1%的CLL患者以及81%的MM患者存在严重维生素D缺乏（<10 ng/mL）。
结论
我们观察到，大多数新诊断的NHL-DLBCL、CLL和MM患者的血清维生素D水平较低。
Zotero 插件